ASCVD Risk Categories
| 10-Year Risk | Risk Category | Statin Therapy Recommendation |
|---|---|---|
| <5% | Low Risk | Heart-healthy lifestyle counseling. No statin indicated. |
| 5–7.5% | Borderline Risk | Consider moderate-intensity statin if risk enhancers present (family history, CAC>0, elevated Lp(a), etc.). Discuss with patient. |
| 7.5–20% | Intermediate Risk | Moderate-intensity statin recommended. Consider CAC scoring if decision uncertain. If diabetic, moderate-to-high intensity statin. |
| >20% | High Risk | High-intensity statin (atorvastatin 40–80mg or rosuvastatin 20–40mg). Consider specialist referral. Risk enhancers may justify earlier statin in diabetic patients. |
About the Pooled Cohort Equations
The ASCVD Pooled Cohort Risk Equations were developed by the American College of Cardiology and American Heart Association in 2013 (Goff DC Jr, et al., Circulation. 2014;129:S49–S73) to estimate 10-year risk of a first ASCVD event — defined as nonfatal myocardial infarction, coronary heart disease death, or stroke. The equations were derived from pooled data from several major cohort studies including ARIC, CARDIA, and Framingham.
The Pooled Cohort Equations use race- and sex-specific regression models, reflecting the fact that cardiovascular risk factors carry different absolute risk weights across population groups. Four separate equations were derived: one each for White males, White females, Black males, and Black females. Each equation incorporates age, total cholesterol, HDL cholesterol, systolic blood pressure, antihypertensive medication use, diabetes status, and smoking status — all variables amenable to clinical intervention or risk modification. The output is a 10-year probability (expressed as a percentage) of experiencing a first atherosclerotic cardiovascular event.
The 2018 ACC/AHA Cholesterol Management Guideline updated the clinical decision framework around the PCE. Rather than applying a rigid treatment threshold, the 2018 guidelines introduced a shared decision-making approach that incorporates the calculated risk alongside risk-enhancing factors (family history, elevated Lp(a), hs-CRP, chronic kidney disease, inflammatory conditions) and, in cases of uncertainty, coronary artery calcium (CAC) scoring as a tie-breaker for the statin treatment decision. This framework acknowledges the known overestimation of risk in the PCE relative to contemporary populations.
How to Use This Calculator
Enter the patient's age (must be 40–79), biological sex, and race (White or African American — see limitations for other racial groups). Enter total cholesterol, HDL cholesterol, and systolic blood pressure in the specified units. Check the boxes for antihypertensive medication use, diabetes mellitus, and current smoking status as applicable. Click "Calculate 10-Year ASCVD Risk" to generate the result.
The calculated risk should be interpreted in clinical context alongside the patient's specific risk-enhancing factors. Risk-enhancing factors present in the guideline include: LDL-C 160 mg/dL or higher, high-sensitivity CRP 2.0 mg/L or higher, lipoprotein(a) 50 mg/dL or higher, ABI below 0.9, metabolic syndrome, chronic kidney disease, premature ASCVD in a first-degree relative (men under 55, women under 65), inflammatory conditions (rheumatoid arthritis, psoriasis, HIV), and history of preeclampsia or premature menopause. If the treatment decision remains uncertain after calculating the 10-year risk and assessing risk enhancers, a coronary artery calcium (CAC) score can help reclassify: CAC of 0 substantially reduces treatment likelihood; CAC of 100 or higher substantially increases it.
What is NOT Captured by ASCVD Risk
- Family history of premature ASCVD — strong independent risk factor that should prompt earlier statin initiation regardless of calculated risk
- Coronary artery calcium (CAC) score — a CAC of 0 substantially lowers risk below what the equation suggests; a CAC ≥100 is a powerful independent indication for statin
- LDL cholesterol — not in the equation despite being a primary modifiable risk factor; use clinical judgment for very elevated LDL
- Lp(a), hs-CRP — emerging risk factors not included; elevated levels can support treatment decisions
- Chronic kidney disease, inflammatory diseases — enhance risk beyond what the equation captures
- Social determinants of health — SDOH factors (food insecurity, housing instability) substantially affect cardiovascular outcomes and are not captured in any calculator
When to Skip the Calculator
Some patients should receive statin therapy regardless of ASCVD risk score:
- LDL ≥190 mg/dL — severe hypercholesterolemia warrants high-intensity statin regardless of risk score
- Diabetes mellitus aged 40–75 — moderate-to-high intensity statin is generally indicated; use risk calculator to help refine intensity
- Clinical ASCVD — patients with known ASCVD need high-intensity statin and are not candidates for primary prevention equations
Limitations & Considerations
Risk overestimation in contemporary patients: Multiple validation studies have demonstrated that the PCE significantly overestimates ASCVD risk in contemporary populations compared to the 1990s cohorts used for derivation. This is attributed to secular trends including better blood pressure control, wider statin use, and declining smoking rates. In practice, the PCE may overestimate risk by approximately 75–150% in some contemporary cohorts. Clinicians should be aware of this when counseling patients near decision thresholds.
Race and ethnicity: The PCE includes only White and African American race-specific equations. For patients of Hispanic, East Asian, South Asian, Native American, or mixed race/ethnicity, there is no validated race-specific equation. The 2018 ACC/AHA guideline recommends using the White equation as an approximation for non-White, non-Black patients while acknowledging that risk may be underestimated (particularly for South Asian patients) or overestimated (for some East Asian populations). This is a recognized limitation of the tool and should be documented.
Exclusion criteria: The PCE should not be used in patients with established ASCVD (prior MI, stroke, angina, coronary revascularization, peripheral artery disease), patients with LDL-C of 190 mg/dL or higher (familial hypercholesterolemia), or patients outside the 40–79 age range. For patients aged 20–39, a lifetime risk estimate approach is recommended by the 2018 guidelines. For patients over 79, individual benefit-risk assessment should guide decisions.
Modifiable risk factor context: The PCE reflects risk at the current level of risk factor values. A patient who recently quit smoking or started antihypertensive therapy will have a lower projected risk going forward than the current score shows if old values are entered. Always use current, stable values for the most accurate estimate.
References
Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S49–S73. doi: 10.1161/01.cir.0000437741.48606.98
Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC Guideline on the Management of Blood Cholesterol. J Am Coll Cardiol. 2019;73(24):e285–e350.